Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Toripalimab by Shanghai Junshi Biosciences for Dermatofibrosarcoma Protuberans (DFSP): Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Dermatofibrosarcoma Protuberans (DFSP). According to...
Toripalimab by Shanghai Junshi Biosciences for Fibrosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Fibrosarcoma. According to GlobalData, Phase...
Toripalimab by Shanghai Junshi Biosciences for Pleomorphic Liposarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Leiomyosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase...
Toripalimab by Shanghai Junshi Biosciences for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Oral Cavity (Mouth) Cancer. According...
Toripalimab by Shanghai Junshi Biosciences for Bone Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Bone Sarcoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Rhabdomyosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase...
Toripalimab by Shanghai Junshi Biosciences for Throat Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Throat Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Neuroendocrine Carcinoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Neuroendocrine Carcinoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Ewing Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Ewing Sarcoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Anal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Anal Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Ureter Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Ureter Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Urethral Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Urethral Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Laryngeal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Laryngeal Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Hypopharyngeal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Bladder Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Bladder Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Prostate Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Prostate Cancer. According to GlobalData,...
JS-006 by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According...
JS-006 by Shanghai Junshi Biosciences for Solid Tumor: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Solid Tumor. According to GlobalData,...
JS-006 by Shanghai Junshi Biosciences for Hepatocellular Carcinoma: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...